AbbVie Inc. (ABBV)
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
AbbVie is a Dividend King that's proven it can successfully navigate patent cliffs. Brookfield Infrastructure offers attractive distributions and has a solid long-term growth strategy.
AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Is This Company Still a Strong Buy After Tripling the S&P 500's Returns?
AbbVie is a superbly managed organization. The company's leaders expertly positioned it for Humira's loss of patent protection.
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Dividend Income Summary: Lanny's August 2024 Summary
Investing in dividend stocks allows you to earn dividend income, the best passive income stream. In August, we (my wife and I) received a dividend income total of $1,415.47. 2023 was up 24%. Eight months down in 2024 and the S&P 500 is still up 14%, despite the recent sell-offs. Unemployment is starting to tick up recently.
Why AbbVie (ABBV) Outpaced the Stock Market Today
AbbVie (ABBV) closed the most recent trading day at $196.42, moving +1.56% from the previous trading session.
3 Things You Need to Know if You Buy AbbVie Stock Today
AbbVie's leadership and revenue mix have changed, and more change is coming. There's a good chance that it will diversify into a new pharmaceutical segment.
3 No-Brainer Dividend Stocks to Buy in September
AbbVie is a Dividend King with solid growth prospects. Merck's looming patent cliff isn't as alarming as it might seem.
Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever
Hims & Hers is rapidly picking up steam in the telehealth industry. UnitedHealth's dominance has created massive wealth for long-term investors.
AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.
AbbVie Stock Post Humira is Still an Attractive Stock to Hold
AbbVie NYSE: ABBV is a global biopharmaceutical company long synonymous with its blockbuster drug, Humira. While the drug's success has propelled AbbVie to great heights, its recent patent expiration has greatly influenced the company's future.
What's Behind The 2x Jump In AbbVie Stock?
AbbVie stock (NYSE: ABBV) has more than doubled in value since early January 2021 - jumping from levels of $90 then to around $195 now - vs. an increase of about 50% for the S&P 500 over this period.
